Related references
Note: Only part of the references are listed.HER2 Testing in Endometrial Serous Carcinoma Time for Standardized Pathology Practice to Meet the Clinical Demand
Natalia Buza
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2021)
Pathological features, immunoprofile and mismatch repair protein expression status in uterine endometrioid carcinoma: focus on MELF pattern of myoinvasion
Angela Santoro et al.
EJSO (2021)
Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer
Young Shin Chung et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2021)
Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features
Amy Joehlin-Price et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2021)
Recent advances in Lynch syndrome
Xi Li et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)
Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity
Douglas Rottmann et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2021)
Interpretation of mismatch repair protein expression using obsolete criteria results in discrepancies with microsatellite instability and mutational testing results. Comment on Hechtman et al. Mod Pathol 2020; 33:871-879
Naveena Singh et al.
MODERN PATHOLOGY (2021)
HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting
Natalia Buza
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2021)
Relationship between morular metaplasia and squamous differentiation in endometrial carcinoma
Antonio Travaglino et al.
PATHOLOGY RESEARCH AND PRACTICE (2021)
Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors
Julie Leclerc et al.
CANCERS (2021)
Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification
Angela Santoro et al.
GYNECOLOGIC ONCOLOGY (2021)
The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study
Willem Jan van Weelden et al.
HUMAN PATHOLOGY (2021)
Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study
Natalia Buza et al.
MODERN PATHOLOGY (2021)
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma
Nicole Concin et al.
VIRCHOWS ARCHIV (2021)
Endometrial Adenocarcinomas With No Specific Molecular Profile: Morphologic Features and Molecular Alterations of Copy-number Low Tumors
Vivienne T. Meljen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2021)
An Emerging Anti-p16 Antibody-BC42 Clone as an Alternative to the Current E6H4 for Use in the Female Genital Tract Pathological Diagnosis: Our Experience and a Review on p16ink4a Functional Significance, Role in Daily-Practice Diagnosis, Prognostic Potential, and Technical Pitfalls
Giuseppe Angelico et al.
DIAGNOSTICS (2021)
New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines
Angela Santoro et al.
CANCERS (2021)
Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma
Danielle C. Costigan et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2020)
HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy
Douglas Rottmann et al.
MODERN PATHOLOGY (2020)
PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells Differences Across Histologic and TCGA-based Molecular Subgroups
Annukka Pasanen et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas
Shuang Zhang et al.
BMC CANCER (2020)
Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens
Anna Plotkin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2020)
Interpretation of somatic POLE mutations in endometrial carcinoma
Alicia Leon-Castillo et al.
JOURNAL OF PATHOLOGY (2020)
Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma
Annukka Pasanen et al.
MODERN PATHOLOGY (2020)
Aberrant non-canonical WNT pathway as key-driver of high-grade serous ovarian cancer development
Gian Franco Zannoni et al.
VIRCHOWS ARCHIV (2020)
Endometrial Carcinomas with a Serous Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations
Niamh Conlon et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification
Soyoun Rachel Kim et al.
GYNECOLOGIC ONCOLOGY (2020)
Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer
Neal C. Fiamchander et al.
FRONTIERS IN IMMUNOLOGY (2020)
Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort.
Britt Kristina Erickson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis
Ling Lu et al.
FRONTIERS IN ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice
Matteo Fassan et al.
PATHOLOGICA (2020)
Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility
Martin Kobel et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2019)
Comparison of Different Scoring Systems in the Assessment of Estrogen Receptor Status for Predicting Prognosis in Endometrial Cancer
Yue Wang et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2019)
Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers
Marisa R. Moroney et al.
GYNECOLOGIC ONCOLOGY (2019)
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
C. Luchini et al.
ANNALS OF ONCOLOGY (2019)
Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer
Umran Kucukgoz Gulec et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2019)
Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review
Willem Jan van Weelden et al.
FRONTIERS IN ONCOLOGY (2019)
Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management
Eman Abdulfatah et al.
GYNECOLOGIC ONCOLOGY (2019)
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
Stephanie M. de Boer et al.
LANCET ONCOLOGY (2019)
TCGA molecular groups of endometrial cancer: Pooled data about prognosis
Antonio Raffone et al.
GYNECOLOGIC ONCOLOGY (2019)
Progesterone and Estrogen Signaling in the Endometrium: What Goes Wrong in Endometriosis?
Ryan M. Marquardt et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The Role of the Cyclin Dependent Kinase Inhibitor p21cip1/waf1 in Targeting Cancer: Molecular Mechanisms and Novel Therapeutics
Samar Al Bitar et al.
CANCERS (2019)
Multiple Targets of the Canonical WNT/β-Catenin Signaling in Cancers
Yves Lecarpentier et al.
FRONTIERS IN ONCOLOGY (2019)
Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma
Stefano Indraccolo et al.
CLINICAL CANCER RESEARCH (2019)
Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+lymphocytes
Suzanne Crumley et al.
MODERN PATHOLOGY (2019)
T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers
Shiho Asaka et al.
MODERN PATHOLOGY (2019)
Immunohistochemical Nuclear Expression of -Catenin as a Surrogate of CTNNB1 Exon 3 Mutation in Endometrial Cancer
Antonio Travaglino et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2019)
The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification
Jun Guan et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2019)
Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma
Aline Talhouk et al.
CLINICAL CANCER RESEARCH (2019)
Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency
Zaibo Li et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2018)
International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013
Joannie Lortet-Tieulent et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer
Hitomi Yamashita et al.
Oncotarget (2018)
International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013
Joannie Lortet-Tieulent et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups
Tjalling Bosse et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer
Jisup Kim et al.
GYNECOLOGIC ONCOLOGY (2018)
The roles of pathology in targeted therapy of women with gynecologic cancers
Rajmohan Murali et al.
GYNECOLOGIC ONCOLOGY (2018)
Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study
Louis J. M. van der Putten et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2018)
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Amanda N. Fader et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers
Giacomo Corrado et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Takeru Wakatsuki et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response
Daniel Temko et al.
JOURNAL OF PATHOLOGY (2018)
Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association
Grace Kim et al.
MODERN PATHOLOGY (2018)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al.
NATURE MEDICINE (2018)
L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile
Felix K. F. Kommoss et al.
BRITISH JOURNAL OF CANCER (2018)
The therapeutic significance of mutational signatures from DNA repair deficiency in cancer
Jennifer Ma et al.
NATURE COMMUNICATIONS (2018)
L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion
Daniela de Freitas et al.
PLOS ONE (2018)
Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies
Malak Abedalthagafi
Oncotarget (2018)
HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
Mari Kylleso Halle et al.
BRITISH JOURNAL OF CANCER (2018)
Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors
Amy Bregar et al.
GYNECOLOGIC ONCOLOGY (2017)
Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis
Josee-Lyne Ethier et al.
GYNECOLOGIC ONCOLOGY (2017)
Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing
Jonathan A. Nowak et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
The genetic landscape of endometrial clear cell carcinomas
Deborah F. DeLair et al.
JOURNAL OF PATHOLOGY (2017)
CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence
Katherine C. Kurnit et al.
MODERN PATHOLOGY (2017)
Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition
Florine A. a Eggink et al.
ONCOIMMUNOLOGY (2017)
Molecular mechanism of estrogen-estrogen receptor signaling
Pelin Yasar et al.
REPRODUCTIVE MEDICINE AND BIOLOGY (2017)
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression
Gulden Menderes et al.
CLINICAL CANCER RESEARCH (2017)
Comprehensive Analysis of Hypermutation in Human Cancer
Brittany B. Campbell et al.
CELL (2017)
Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification
Anthony N. Karnezis et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2017)
Drug-biomarker co-development in oncology-20 years and counting
Julianne D. Twomey et al.
DRUG RESISTANCE UPDATES (2017)
PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors
Emily A. Sloan et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Integrated Molecular Characterization of Uterine Carcinosarcoma
Andrew D. Cherniack et al.
CANCER CELL (2017)
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
N. Colombo et al.
ANNALS OF ONCOLOGY (2016)
POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance
Fernando Bellido et al.
GENETICS IN MEDICINE (2016)
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H. Baumeister et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology
Angela N. Bartley et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts
Ellen Stelloo et al.
CLINICAL CANCER RESEARCH (2016)
Conditional deletion of L1CAM in human neurons impairs both axonal and dendritic arborization and action potential generation
Christopher Patzke et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer
Inge C. Van Gool et al.
MODERN PATHOLOGY (2016)
Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer
Zhongfu Mo et al.
ONCOLOGY LETTERS (2016)
The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Jiandong Chen
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
A panoply of errors: polymerase proofreading domain mutations in cancer
Emily Rayner et al.
NATURE REVIEWS CANCER (2016)
Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
Martin Kobel et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2016)
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study
Enric Domingo et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
PD-1, PD-L1 expression in 1599 gynecological cancers: Implications for immunotherapy
T. J. Herzog et al.
GYNECOLOGIC ONCOLOGY (2015)
Should Endometrial Clear Cell Carcinoma be Classified as Type II Endometrial Carcinoma?
Hyo Sook Bae et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2015)
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
Ellen Stelloo et al.
MODERN PATHOLOGY (2015)
Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis
E. Zeynep Erson-Omay et al.
NEURO-ONCOLOGY (2015)
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
Brooke E. Howitt et al.
JAMA ONCOLOGY (2015)
Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
David N. Church et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
In-depth molecular profiling of the biphasic components of uterine carcinosarcomas
Melissa K. McConechy et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2015)
Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer
Anne M. Mills et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Which threshold for ER positivity? a retrospective study based on 9639 patients
M. Yi et al.
ANNALS OF ONCOLOGY (2014)
Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'Care for CMMRD' (C4CMMRD)
Katharina Wimmer et al.
JOURNAL OF MEDICAL GENETICS (2014)
Wnt/Catenin Signaling in Adult Stem Cell Physiology and Disease
Alexander Ring et al.
STEM CELL REVIEWS AND REPORTS (2014)
Lack of Estrogen Receptor-α Is Associated with Epithelial-Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma
Elisabeth Wik et al.
CLINICAL CANCER RESEARCH (2013)
Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial
Jone Trovik et al.
EUROPEAN JOURNAL OF CANCER (2013)
Marked Heterogeneity of HER2/NEU Gene Amplification in Endometrial Serous Carcinoma
Natalia Buza et al.
GENES CHROMOSOMES & CANCER (2013)
Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma
Jutta Huvila et al.
GYNECOLOGIC ONCOLOGY (2013)
DNA polymerase ? and exonuclease domain mutations in endometrial cancer
David N. Church et al.
HUMAN MOLECULAR GENETICS (2013)
The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer
Gian Franco Zannoni et al.
HUMAN PATHOLOGY (2013)
Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice
Natalia Buza et al.
MODERN PATHOLOGY (2013)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome
C. Krakstad et al.
BRITISH JOURNAL OF CANCER (2012)
HER2/neu as a Potential Target for Immunotherapy in Gynecologic Carcinosarcomas
Federica Guzzo et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2012)
Neoadjuvant Therapy Induces Loss of MSH6 Expression in Colorectal Carcinoma
Fei Bao et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Microsatellite Instability in Colorectal Cancer
C. Richard Boland et al.
GASTROENTEROLOGY (2010)
The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas
Martin Koebel et al.
JOURNAL OF PATHOLOGY (2010)
Prognostic significance and clinical importance of estrogen receptor α and β in human endometrioid adenocarcinomas
Ioannis Mylonas
ONCOLOGY REPORTS (2010)
An Optimized Pentaplex PCR for Detecting DNA Mismatch Repair-Deficient Colorectal Cancers
Ajay Goel et al.
PLOS ONE (2010)
GSK3: a multifaceted kinase in Wnt signaling
Dianqing Wu et al.
TRENDS IN BIOCHEMICAL SCIENCES (2010)
TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
Magali Olivier et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
Bryan T. MacDonald et al.
DEVELOPMENTAL CELL (2009)
Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer
Vincent Jongen et al.
GYNECOLOGIC ONCOLOGY (2009)
A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study
Howard D. Homesley et al.
GYNECOLOGIC ONCOLOGY (2009)
p21 in cancer: intricate networks and multiple activities
Tarek Abbas et al.
NATURE REVIEWS CANCER (2009)
L1 and NCAM adhesion molecules as signaling coreceptors in neuronal migration and process outgrowth
Ralf S. Schmid et al.
CURRENT OPINION IN NEUROBIOLOGY (2008)
Transcriptional control of human p53-regulated genes
Todd Riley et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: A Gynecologic Oncology Group Study
Meenakshi Singh et al.
GYNECOLOGIC ONCOLOGY (2007)
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype:: Lessons from recent developments in the IARC TP53 database
Audrey Petitjean et al.
HUMAN MUTATION (2007)
The many ways of Wnt in cancer
Paul Polakis
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
Frizzled/RYK mediated signalling in axon guidance
Paola Bovolenta et al.
DEVELOPMENT (2006)
Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment I
R. A. Walker
HISTOPATHOLOGY (2006)
Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers
CA Hamilton et al.
BRITISH JOURNAL OF CANCER (2006)
Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization
AD Santin et al.
GYNECOLOGIC ONCOLOGY (2005)
Convergence of Wnt, β-catenin, and cadherin pathways
WJ Nelson et al.
SCIENCE (2004)